Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Multisystem Cell Therapy for Improvement of Urinary Continence (MUSIC)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Austria,Germany,Switzerland,Netherlands,United Kingdom
Call: Clinical research on regenerative medicine (H2020-SC1-2016-RTD, 2016)
Start date: 2017-01-01
End date: 2022-03-31
Duration (months): 63.0
Total project cost (EUR): 6623628.75
EU funding (EUR): 2349521.25
Participants: 7
Project status: CLOSED

Stress Urinary Incontinence (SUI) is a disease affecting over 200 million people worldwide. It represents a condition with a prevalence of 20-50% in women, thereby creating an immense socio-economic burden. The currently available treatment strategies entail various complications and offer only short-term relief to the patients. Tissue engineering using autologous cells offers a feasible alternative for functional restoration of the damaged urinary sphincter muscle and represents an ideal treatment option that could reverse the underlying pathologic conditions. MUSIC aims at translating basic knowledge on regenerative medicine (RM) and stem cell therapy into the clinic by undertaking a "first-in-man" multisystem study using autologous muscle precursor cells (MPCs) in a combination with neuromuscular electromagnetic stimulation (NMES) in 40 female patients. We will carry out the specific tasks to prove safety and efficacy of the proposed novel multilevel treatment as well as reproducibility of the therapeutic effect. Additional objectives are optimization of the advanced-therapy medicinal product (ATMP) towards totally xeno-free and facilitated manufacturing as well as the introduction of a novel injection technique for more efficient and precise implantation of the final product. Combining expertise, MUSIC features a unique infrastructure, including the knowledge of experts in the fields of RM, urology, cellular biology and biomaterials throughout Europe (CH, NL, UK, A, D). The MUSIC consortium has an exclusive opportunity to determine the validity of this MPC cellular treatment in combination with NMES and to further improve its feasibility and clinical efficacy. The ultimate goal is to significantly improve the patients` quality of life and to exploit a future commercial opportunity by expanding the know-how to various smaller RM centers and companies within Europe, thus, making personalized medicine using autologous cells a more feasible SUI treatment option.

Keywords: muscle precursor cells,stress urinary incontinence,neuromuscular electromagnetic stimulation,xenofree facilitated manufacturing process
GIS-BASED INFRASTRUCTURE MANAGEMENT SYSTEM FOR OPTIMIZED RESPONSE TO EXTREME EVENTS OF TERRESTRIAL TRANSPORT NETWORKS (SAFEWAY)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: Research and Innovation actions
Countries involved: Spain,Spain,Italy,Spain,Switzerland,Poland,Norway,United States,Netherlands,Netherlands,United Kingdom,United Kingdom,Portugal,Portugal
Call: Resilience to extreme (natural and man-made) events (H2020-MG-2017-Two-Stages, 2017)
Start date: 2018-09-01
End date: 2022-02-28
Duration (months): 42.0
Total project cost (EUR): 4535600.0
EU funding (EUR): 4521100.0
Participants: 17
Project status: CLOSED

According to European TEN-T guidelines, due consideration must be given to the risk assessments and adaptation measures during infrastructure planning, in order to improve resilience to disasters. SAFEWAY’s aim is to design, validate and implement holistic methods, strategies, tools and technical interventions to significantly increase the resilience of inland transport infrastructure. SAFEWAY leads to significantly improved resilience of transport infrastructures, developing a holistic toolset with transversal application to anticipate and mitigate the effects extreme events at all modes of disaster cycle: 1) “Preparation”: substantial improvement of risk prediction, monitoring and decision tools contributing to anticipate, prevent and prepare critical assets for the damage impacts; 2)“Response and Recovery”: the incorporation of SAFEWAY IT solutions into emergency plans, and real-time optimal communication with operators and end users (via crowdsourcing and social media); 3)“Mitigation”: improving precision in the adoption of mitigation actions (by impact analysis of different scenarios) together with new construction systems and materials, contributing to the resistance & absorption of the damage impact. SAFEWAY consortium has 15 partners that cover multidisciplinary and multisectorial business fields associated with resilience of transport infrastructure in Europe: national transport infrastructure managers & operators, a main global infrastructure operator, partners able to provide various data sources with large coverage in real time, comprehensive ITC solutions, and leading experts in resilience, risk databases, remote sensing-based inspection, and decision systems based on predictive modelling. SAFEWAY will carry-out 4 real case studies distributed through 4 countries, linked to 5 corridors of the TEN-T Core Network. SAFEWAY has as main expected impacts: 1) at least 20% improvement in mobility and 2) at least 20% lower cost of infrastructure maintenance.

Keywords: resilience,infrastructure management,predictive maintenance,decision support system
Ultrasensitive Quantification of Proteins based on Amplification of DNA Displaced from DNA Aptamer Duplex using Semiconductor Technology (DNAsensPROT)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: United Kingdom
Call: ERC Proof of Concept Grant (ERC-2018-PoC, 2018)
Start date: 2018-12-01
End date: 2020-11-30
Duration (months): 24.0
Total project cost (EUR): 149956.25
EU funding (EUR): 149956.0
Participants: 1
Project status: CLOSED

The life expectancy in both EU and US fell in 2015. A third of premature deaths could be preventable and large part is due to obesity – a major risk factor for many chronic diseases including diabetes. Worldwide about 40% of adults are overweight and 13% obese. Regulation of food metabolism is becoming one of the main issues relevant to human health today. Obesity is preventable, however there are no currently available non-invasive and cost-effective obesity treatments, pointing to the need of novel diagnostic and prognostic tests. Leptin, a gut-hormone protein, has been shown to be crucial in regulating appetite and weight. Its concentration is proportional to the body fat mass, and changes at a greater rate compared to weight loss, therefore it can be used as a key measure of diet efficiency. Strong correlation between plasma and salivary leptin levels allows monitoring leptin in saliva, and provides point-of-care (PoC) personalised insight into the success of individual weight loss programs. During our ERC Synergy Grant we have developed an aptamer based approach to perform quantitative detection of protein molecules using nucleic acid amplification to overcome the complexities of current methods to enable PoC detection. The key idea (patent pending) is to amplify and quantify DNA displaced from DNA-aptamer complexes by Leptin molecules with real-time Loop Mediated Isothermal Amplification. We will use an Ion Sensitive Field Effect Transistor lab-on chip arrays. Now we need funds to further develop this technology and create a PoC platform to provide linear label-free ultrasensitive protein detection, reducing complexity, time-to-result and cost of the assay. Furthermore, the development of this novel molecular method will enable quantification of a broader number of protein targets and create one of the most sensitive PoC techniques for protein quantification, with applications far beyond appetite control (obesity, anorexia etc) management.

Keywords: dna amplification,aptamer,semiconductor technology,point of care,leptin,obesity,proteomics
Small Summaries for Big Data (SSBD)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Computer science and informatics
Panel description: Informatics and information systems, computer science, scientific computing, intelligent systems
Countries involved: United Kingdom
Call: ERC Consolidator Grant (ERC-2014-CoG, 2014)
Start date: 2015-05-01
End date: 2021-04-30
Duration (months): 72.0
Total project cost (EUR): 1565502.0
EU funding (EUR): 1565502.0
Participants: 1
Project status: CLOSED

A fundamental challenge in processing the massive quantities of information generated by modern applications is in extracting suitable representations of the data that can be stored, manipulated and interrogated on a single machine. A promising approach is in the design and analysis of compact summaries: data structures which capture key features of the data, and which can be created effectively over distributed data sets. Popular summary structures include the Bloom filter, which compactly represents a set of items, and sketches which allow vector norms and products to be estimated. These are very attractive, since they can be computed in parallel and combined to yield a single, compact summary of the data. Yet the full potential of summaries is far from being fully realized. The Principal Investigator will lead a team, working on important problems around creating Small Summaries for Big Data. The goal is to substantially advance the state of the art in data summarization, to the point where accurate and effective summaries are available for a wide array of problems, and can be used seamlessly in applications that process big data. Several directions will be pursued, including: designing and evaluating new summaries for fundamental computations such as tracking the data distribution; summary techniques for complex structures, such as massive matrices, massive graphs, and beyond; and summaries that allow the verification of outsourced computation over big data. Success in any one of these areas could lead to substantial impact on practice, as evidenced by the influence of existing summary techniques. Support in the form of a five-year research grant will allow the PI to consolidate his research in this area, and build an expert team to focus on these challenging algorithmic questions.

Keywords: synposes,sketches,data streams,verification of computation
A combination of approaches from the molecular to the integrative plant level to understand the bases of stomatal responses to CO2 and their variability (STOCOVAR)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2016, 2016)
Start date: 2018-09-01
End date: 2020-08-31
Duration (months): 24.0
Total project cost (EUR): 183454.8
EU funding (EUR): 183454.8
Participants: 1
Project status: CLOSED

Understanding plant responses to rising atmospheric CO2 is of major interest given the necessity to select and develop new crop cultivars that will perform better in a changing global climate. By regulating the exchange of water and CO2 between the interior of the leaf and the atmosphere, stomata -the pores at the leaf surface- play a major role in CO2-mediated processes. Stomatal aperture is constantly adjusted, in response to internal cues and external environmental signals, through turgor changes of the two guard cells that surround the pore. Plants respond to elevated CO2 levels by reducing stomatal aperture, and recent advances have shed light on the intracellular machinery responsible for this response. However, little is understood about the variability in stomatal responses to CO2, both among and within species. This project will decipher the main factors responsible for variations in stomatal responses to CO2. It will specifically address the roles of ABA-signalling, photosynthesis and stomatal morphology in the response of stomatal conductance (gs) to CO2 and how this impacts on plant performance. These will be investigated from the cellular to the level of the whole plant by using the model plant Arabidopsis thaliana and major European crops. Genetic diversity will be used in different forms (mutants, association studies, inter-specific comparison) to identify the causal factors of variation. The knowledge gained into gs responses will be integrated into predictive models for water-use efficiency to scale-up to whole plant performance.

Keywords: stomata,carbon dioxide,water use efficiency,abscisic acid,photosynthesis
ETVAX – the first oral vaccine for protection against traveller’s diarrhoea caused by ETEC (ETVAX)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Sweden
Call: Supporting innovative SMEs in the healthcare biotechnology sector (H2020-SMEINST-2-2016-2017, 2017)
Start date: 2017-06-01
End date: 2020-05-31
Duration (months): 36.0
Total project cost (EUR): 2992750.0
EU funding (EUR): 2992750.0
Participants: 1
Project status: CLOSED

This project will perform a Phase II study of ETVAX – an oral vaccine against traveller’s diarrhoea (TD) caused by enterotoxigenic E. coli bacteria (ETEC). ETVAX has a strong potential to be the first vaccine with a full ETEC indication. TD caused by enterotoxigenic E. coli bacteria is the most common illness that affects travellers traveling in the developing regions. Currently, there is no approved method for preventing TD. Travellers are recommended to use off-label antibiotics such as Rifaximin or the cholera vaccine Dukoral to prevent TD. In business terms, there exists a strong business opportunity in developing and commercializing an effective and safe ETEC vaccine. Scandinavian Biopharma is the first SME positioned to capture this opportunity. The envisaged Phase II study will allow Scandinavian Biopharma take the key step towards the commercialization of ETVAX. The targeted users of are travellers visiting tropical and subtropical countries. Their number is forecasted to reach 190 million by 2020. Their key need is to prevent TD which can ruin a significant part of a vacation or a business trip. ETVAX will meet this needs by being safe, efficient and easy to use. The project delivers an ultimate EU added value by offering the first ETEC vaccine with proven immunogenicity, safety and efficacy. From the scientific perspective, this means that the project fills the gap in the vaccine research on the EU and global level as no other efficient methods for prevention of TD have been proposed on the market to date. The introduction of ETVAX will ultimately decrease number of TD cases among travellers, decrease number of patients with irritable bowel syndrome or other chronic diseases connected to TD, as well as decrease healthcare costs and productivity losses on the EU level. If successfully validated and accepted by regulatory bodies, ETVAX will take Scandinavian Biopharma to a new level of competitiveness and growth.

Keywords: oral vaccine,traveller s diarrhoea,enterotoxigenic e coli bacteria etec,phase ii study,prevention
Novel Immunotherapeutic Vaccine for the treatment of Alzheimer’s disease (IMMOVA)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Biotechnology
Action type: SME instrument
Countries involved: Sweden
Call: Dedicated support to biotechnology SMEs closing the gap from lab to market (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-03-01
End date: 2017-08-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The objective of this project is to develop a business plan for the continued clinical development and commercialisation of ALZ-101 – a novel therapeutic Alzheimer´s disease (AD) vaccine candidate designed to prevent neurodegeneration in the brain. AD is a therapeutic area in dire need of effective treatments. The disease, which primarily afflicts the elderly (65+), irreversbly destroys brain cells and affects the patient’s cognitive ability. The exact mechanisms leading to AD are unknown. However, it has been found that the disease is linked to the aggregation and deposition of Aβ1-42 – one of the isoforms of fibrous Aβ peptide - into senile plaques in the brain. In recent years, significant efforts have been made to attempt targeting the clearance of Aβ1-42 through the administration of Aβ antigens (active immunotherapy) or anti-Aβ anti-bodies (passive immunotherapy). However, the development has been fraught with difficulties. Aβ1-42 oligomers are inherently unstable and heterogeneous. This precludes the development of efficient therapies. Alzinova owns the AβCC peptide™ technology which allows for the development of a vaccine that specifically targets the endogenous substance that causes disease – a feat made possible by the unprecedented capability to stabilise the antigen. The product will be ready to enter the clinical trial in humans by the end of 2017. In the Phase 1 project, we will develop a business plan that will guide the future clinical studies and commercialisation (to be included in the Phase 2 project). The strategy is to take the product to the Phase I/IIa level and thereafter acquire strategic partner for continued clinical studies and market launch. Fighting AD is an EU-wide challenge as it affects 7.3 million people within the EU-27 countries. The effects of AD are devastating not only for the patients, but also for their families. ALZ-101 delivers in this context a strong EU-added value by its potential to stop the progression of AD.

Keywords: alzheimer s disease therapy,vaccine candidate,amyloid beta peptide clearance
Real time, automatic and remote-activated sampling system for industrial odour emissions compliant with the European Standard EN 13725 (ODORPREP)

Framework: Horizon 2020 — Societal Challenges
Programme: Climate action, environment,  resource efficiency and raw materials
Action type: SME instrument
Countries involved: Italy
Call: Boosting the potential of small businesses in the areas of climate action, environment, resource efficiency and raw materials (H2020-SMEINST-2-2016-2017, 2016)
Start date: 2017-03-01
End date: 2019-02-28
Duration (months): 24.0
Total project cost (EUR): 1425125.0
EU funding (EUR): 997587.5
Participants: 1
Project status: CLOSED

With 25 employees, LabSevice Analytica was created 22 years ago to commercialise certified reference material and dedicated instruments for the analysis of environmental and food samples. Since 2012, LabService has been developing ODORPREP. Once fully in the market in 2019, ODORPREP will be the first Real Time, Automatic and Remote Sampling System for Odour Emissions designed in response to the Quality Air Standard for "Determination of odour concentration by dynamic olfactometry" (10/2004). The 2 main targeted groups of ODORPREP will be industrial companies (oil refining, chemistry industry and livestock), responsible for controlling its odour emissions, and the competent authorities in charge of enforcing the odour legislation. OdorPrep is composed by 3 components-steps integrated into the network: 1) A trigger system (protected under the trademark OdourTel®) which consists of a telephonic network that registers systematically the population complaints allowing for real-time detection. 2) An automatic sampling system which collects air samples at the moment of a significant odour event. Being a real-time solution, it enables end-users (industries) to rapid response to any security issue that may arise due to uncontrolled emissions. 3) A network of accredited laboratories which analyse the samples according to European standards (EN13725). OdorPrep selling price is €10,000/unit, more affordable compared to current field olfatometers (€50,000). Monitoring costs are lower, as there is no on site surveillance. For the sampling system we will use sample bags of Nalophan™ for 10€/bag (1,000€ per 100m tube), five times cheaper than Teflon bags. OdorPrep will contribute to prevent and control odour pollutant emissions, allowing to perform a high number of samples at a competitive cost (in the lower market ranges 150-200€/sample), with the added value of quality representativeness measurements (EN13725).

Keywords: odour monitoring,odour impact,en13725,dinamic olfactometry,neighbouhood complaints,quality life,odour sample
Advanced ultra-wideband Radar for Integrated Applications (ARIA)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure societies - protecting freedom and security of Europe and its citizens
Action type: SME instrument
Countries involved: Italy
Call: Engaging SMEs in security research and development (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-08-01
End date: 2017-11-30
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Cover Sistemi Srl has managed to provide innovative solutions for its commercial clients in perimeter intruder detection but never has there been a solution to give a detailed, zone specific, multiple object sensing and precise 3D radar mapping of objects. ARIA is our novel radar sensor with disruptive technology enabling 3D mapping of objects and resulting in people identification, multiple people tracking and selection of zone of surveillance. This technology has never been attempted in any commercial device, making this innovation unchallenged in the perimeter intruder alarms market today. This will result in more safe, reliable and difficult to circumvent home, industrial and commercial perimeter intruder alarms, keeping at bay criminals and terrorists. ARIA will be able to perform this feat at micro-scale integration through strategic partnerships in Europe, making it the best sensor for use in perimeter intruder detection due to its capability of ease to hide in any casing. The small form factor to be packed with high-speed sensing and IoT capabilities gives it some buying drivers of low cost, remote sensing, precise and accurate small packaged sensor for use anywhere and low power consumption. An exhaustive Feasibility Study will bring ARIA into commercialization investment (which will see a positive ROI within 3 years). In 5 years, it shall achieve significant market share in its category as perimeter security system with a conservative accumulated turnover of €14 million for the 2020-2024 period. Cover Sistemi will also bring to the industry 18-20 new jobs in 5 years after commercialisation of ARIA. Besides its breakthrough in expanding perimeter intruder alarm functions, other great potentials (spin-offs) are use of ARIA in healthcare, industrial machine safety, and utility conservation control in homes/buildings.

Keywords: ultra wideband,radar,beam forming,security,perimeter intruder alarm,security sensor,integrated,solution,sensitivity,specificity